Cancer name Kidney Renal Clear Cell Carcinoma
Cancer Type KIRC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment rhIL-37
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature Bcl-2
Official Symbol BCL2
Mode of action PROT_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Accordingly, as shown in Fig.3c, d, pSTAT3 Y705 level was reduced by rhIL-37. Meanwhile,the expressions of Bcl-2 and cyclin D1 were also inhibitedby rhIL-37 in these cells.
PMID 26464282
Title IL-37 mediates the antitumor activity in renal cell carcinoma.